Publications

ASO Visual Abstract: Delta Radiomic Features Predict Resection Margin Status and Overall Survival in Neoadjuvant-Treated Pancreatic Cancer Patients

Wang K, Karalis JD, Elamir A, Bifolco A, Wachsmann M, Capretti G, Spaggiari P, Enrico S, Balasubramanian K, Fatimah N, Pontecorvi G, Nebbia M, Yopp A, Kaza R, Pedrosa I, Zeh H, Polanco P, Zerbi A, Wang J, Aguilera T, Ligorio M 2024 Apr 31 2664-2665

Delta Radiomic Features Predict Resection Margin Status and Overall Survival in Neoadjuvant-Treated Pancreatic Cancer Patients

Wang K, Karalis JD, Elamir A, Bifolco A, Wachsmann M, Capretti G, Spaggiari P, Enrico S, Balasubramanian K, Fatimah N, Pontecorvi G, Nebbia M, Yopp A, Kaza R, Pedrosa I, Zeh H, Polanco P, Zerbi A, Wang J, Aguilera T, Ligorio M 2024 Apr 31 2608-2620

AXL/WRNIP1 Mediates Replication Stress Response and Promotes Therapy Resistance and Metachronous Metastasis in HER2+ Breast Cancer

Marquez-Palencia M, Herrera LR, Parida PK, Ghosh S, Kim K, Das NM, Gonzalez-Ericsson PI, Sanders ME, Mobley BC, Diegeler S, Aguilera TA, Peng Y, Lewis CM, Arteaga CL, Hanker AB, Whitehurst AW, Lorens JB, Brekken RA, Davis AJ, Malladi S 2024 Mar 84 675-687

Stereotactic body radiotherapy plus rucosopasem in locally advanced or borderline resectable pancreatic cancer: GRECO-2 phase II study design

Hoffe SE, Aguilera TA, Parikh PJ, Ghaly MM, Herman JM, Caster JM, Kim DW, Costello J, Malafa MP, Moser EC, Kennedy EP, Terry K, Kurman M 2024 20 437-446

Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial

Taniguchi CM, Frakes JM, Aguilera TA, Palta M, Czito B, Bhutani MS, Colbert LE, Abi Jaoude J, Bernard V, Pant S, Tzeng CW, Kim DW, Malafa M, Costello J, Mathew G, Rebueno N, Koay EJ, Das P, Ludmir EB, Katz MH, Wolff RA, Beddar S, Sawakuchi GO, Moningi S, Slack Tidwell RS, Yuan Y, Thall PF, Beardsley RA, Holmlund J, Herman JM, Hoffe SE 2023 Dec 24 1387-1398

Simultaneous selection of nanobodies for accessible epitopes on immune cells in the tumor microenvironment

Sekar TV, Elghonaimy EA, Swancutt KL, Diegeler S, Gonzalez I, Hamilton C, Leung PQ, Meiler J, Martina CE, Whitney M, Aguilera TA 2023 Dec 14

Local Control Following Stereotactic Body Radiation Therapy for Liver Oligometastases: Lessons from a Quarter Century

Mheid S, Allen S, Ng SS, Hall WA, Sanford NN, Aguilera TA, Elamir AM, Bahij R, Intven MP, Radhakrishna G, Mohamad I, De Leon J, Tan H, Lewis S, Gani C, Stanecu T, Dell’Acqua V, Hosni A 2023 Oct 30 9230-9243

Ablative Radiation Therapy in Oligometastatic Pancreatic Cancer to Delay Polyprogression, Limit Chemotherapy, and Improve Outcomes

Elamir AM, Karalis JD, Sanford NN, Polanco PM, Folkert MR, Porembka MR, Kazmi SA, Maddipati R, Zeh HJ, Timmerman RD, Zhang S, Ligorio M, Beg MS, Aguilera TA 2022 Nov 114 792-802

Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Preclinical Models Enhances Single-Agent Immune Checkpoint Blockade

Moore C, Hsu CC, Chen WM, Chen BP, Han C, Story M, Aguilera T, Pop LM, Hannan R, Fu YX, Saha D, Timmerman R 2021 Aug 110 1306-1316

Disparities in characteristics, access to care, and oncologic outcomes in young-onset colorectal cancer at a safety-net hospital

Fangman BD, Goksu SY, Chowattukunnel N, Beg MS, Sanford NN, Sanjeevaiah A, Cox J, Folkert MR, Aguilera TA, Mathews J, Pogacnik JS, Khatri G, Olson C, Polanco PM, Verma U, Hsiehchen D, Jones A, Kainthla R, Kazmi SM 2021 May 17 E614-E622

Trends and Factors Associated with Receipt of Upfront Surgery for Stage II to III Rectal Adenocarcinoma in the United States, 2006 to 2016

Hein DM, Ahn C, Aguilera TA, Folkert MR, Sanford NN 2021 May 44 187-194

Long-Term Results of a Phase 1 Dose-Escalation Trial and Subsequent Institutional Experience of Single-Fraction Stereotactic Ablative Radiation Therapy for Liver Metastases

Folkert MR, Meyer JJ, Aguilera TA, Yokoo T, Sanford NN, Rule WG, Mansour J, Yopp A, Polanco P, Hannan R, Nedzi LA, Timmerman RD 2021 Apr 109 1387-1395

Patterns of Dose Escalation Among Patients With Esophageal Cancer Undergoing Definitive Radiation Therapy: 2006-2016

Zhang-Velten ER, Eraj SA, Hein DM, Aguilera TA, Folkert MR, Sanford NN 2021 Mar 6

Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in Combination with High Dose Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (PC)

Hoffe S, Frakes JM, Aguilera TA, Czito B, Palta M, Brookes M, Schweizer C, Colbert L, Moningi S, Bhutani MS, Pant S, Tzeng CW, Tidwell RS, Thall P, Yuan Y, Moser EC, Holmlund J, Herman J, Taniguchi CM 2020 Dec 108 1399-1400

Trends in Primary Surgical Resection and Chemotherapy for Metastatic Colorectal Cancer, 2000-2016

Sanford NN, Folkert MR, Aguilera TA, Beg MS, Kazmi SA, Sanjeevaiah A, Zeh HJ, Farkas L 2020 Dec 43 850-856

Racial Disparities in Time to Treatment Initiation and Outcomes for Early Stage Anal Squamous Cell Carcinoma

Goksu SY, Ozer M, Kazmi SM, Aguilera TA, Ahn C, Hsiehchen D, Sanjeevaiah A, Maxwell MC, Beg MS, Sanford NN 2020 Nov 43 762-769

Recent Trends and Overall Survival of Young Versus Older Adults with Stage II to III Rectal Cancer Treated with and without Surgery in the United States, 2010-2015

Sanford NN, Dee EC, Ahn C, Kazmi SA, Beg MS, Folkert MR, Aguilera TA, Polanco PM, Pogacnik JS, Sher DJ 2020 Oct 43 694-700

Feasibility and Outcome of Routine Use of Concurrent Chemoradiation in HIV-positive Patients with Squamous Cell Anal Cancer

Leiker AJ, Wang CJ, Sanford NN, Aguilera TA, Karri S, Beg MS, Kazmi SA, Olson C, Matthews JA, Abdelnaby A, Meyer JJ, Folkert MR 2020 Oct 43 701-708

Targeting TAM to Tame Pancreatic Cancer

von Itzstein MS, Burke MC, Brekken RA, Aguilera TA, Zeh HJ, Beg MS 2020 Oct 15 579-588

Distinct clinical characteristics in young-onset pancreatic neuroendocrine tumor

Goksu SY, Ozer M, Kazmi SM, Sanford NN, Aguilera TA, Ahn C, Hsiehchen D, Sanjeevaiah A, Khosama L, Bleeker J, Atiq M, Beg MS 2020 Sep 12 1-15

Cancer-associated fibroblasts: Versatile players in the tumor microenvironment

Ganguly D, Chandra R, Karalis J, Teke M, Aguilera T, Maddipati R, Wachsmann MB, Ghersi D, Siravegna G, Zeh HJ, Brekken R, Ting DT, Ligorio M 2020 Sep 12 1-35

Stage-specific Conditional Survival among Young (Age below 50 y) Versus Older (Age 50 y and Above) Adults with Colorectal Cancer in the United States

Sanford NN, Ahn C, Beg MS, Sanjeevaiah A, Kazmi SA, Folkert MR, Aguilera TA, Sher DJ 2020 Jul 43 526-530

Induced tumor heterogeneity reveals factors informing radiation and immunotherapy combinations

Aguilera TA, Elghonaimy EA, Shehade H, Rafat M, Castellini L, Jiang D, Kariolis M, Koong AC, Le QT, Ellies LG, Rankin EB, Graves EE, Giaccia AJ 2020 Jun 26 2972-2985

Patterns of Care for Stage II-III Rectosigmoid Cancers in the United States, 2004-2015

Sanford NN, Aguilera TA, Beg MS, Sanjeevaiah A, Hong TS, Wo JY, Folkert MR 2020 May 43 311-318

Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance

Nambiar DK, Aguilera T, Cao H, Kwok S, Kong C, Bloomstein J, Wang Z, Rangan VS, Jiang D, Von Eyben R, Liang R, Agarwal S, Dimitrios Colevas A, Korman A, Allen CT, Uppaluri R, Koong AC, Giaccia A, Le QT 2019 Dec 129 5553-5567

Sociodemographic disparities in the receipt of adjuvant chemotherapy among patients with resected stage I-III pancreatic adenocarcinoma

Sanford NN, Aguilera TA, Folkert MR, Ahn C, Mahal BA, Zeh H, Beg MS, Mansour J, Sher DJ 2019 17 1292-1300

The use of texture-based radiomics CT analysis to predict outcomes in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy

Starkov P, Aguilera TA, Golden DI, Shultz DB, Trakul N, Maxim PG, Le QT, Loo BW, Diehn M, Depeursinge A, Rubin DL 2019 92

Macrophages promote circulating tumor cell-mediated local recurrence following radiotherapy in immunosuppressed patients

Rafat M, Aguilera TA, Vilalta M, Bronsart LL, Soto LA, Von Eyben R, Golla MA, Ahrari Y, Melemenidis S, Afghahi A, Jenkins MJ, Kurian AW, Horst KC, Giaccia AJ, Graves EE 2018 Aug 78 4241-4252

Molecular pathways: Oncologic pathways and their role in T-cell exclusion and immune evasion - A new role for the AXL receptor tyrosine kinase

Aguilera TA, Giaccia AJ 2017 Jun 23 2928-2933

Reprogramming the immunological microenvironment through radiation and targeting Axl

Aguilera TA, Rafat M, Castellini L, Shehade H, Kariolis MS, Hui AB, Stehr H, Von Eyben R, Jiang D, Ellies LG, Koong AC, Diehn M, Rankin EB, Graves EE, Giaccia AJ 2016 Dec 7

A 3-D Riesz-Covariance Texture Model for Prediction of Nodule Recurrence in Lung CT

Cirujeda P, Cid YD, Muller H, Rubin D, Aguilera TA, Loo BW, Diehn M, Binefa X, Depeursinge A 2016 Dec 35 2620-2630

Early-stage non-small cell lung cancer: Quantitative imaging characteristics of 18F fluorodeoxyglucose PET/CT allow prediction of distant metastasis

Wu J, Aguilera T, Shultz D, Gudur M, Rubin DL, Loo BW, Diehn M, Li R 2016 Oct 281 270-278

Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow

Johnson RW, Finger EC, Olcina MM, Vilalta M, Aguilera T, Miao Y, Merkel AR, Johnson JR, Sterling JA, Wu JY, Giaccia AJ 2016 Sep 18 1078-1089

3D Riesz-wavelet based Covariance descriptors for texture classification of lung nodule tissue in CT

Cirujeda P, Muller H, Rubin D, Aguilera TA, Loo BW, Diehn M, Binefa X, Depeursinge A 2015 Nov 7909-7912

The end of the hypoxic epoch

Aguilera TA, Giaccia AJ 2015 Apr 91 895-897

In vivo fluorescence imaging of atherosclerotic plaques with activatable cell-penetrating peptides targeting thrombin activity

Olson ES, Whitney MA, Friedman B, Aguilera TA, Crisp JL, Baik FM, Jiang T, Baird SM, Tsimikas S, Tsien RY, Nguyen QT 2012 4 595-605

Spiers memorial lecture: Breeding and building molecular spies

Shu X, Lev-Ram V, Olson ES, Aguilera TA, Jiang T, Whitney M, Crisp JL, Steinbach P, Deerinck T, Ellisman MH, Ellies LG, Nguyen QT, Tsien RY 2011 149 9

Fast 18F labeling of a near-infrared fluorophore enables positron emission tomography and optical imaging of sentinel lymph nodes

Ting R, Aguilera TA, Crisp JL, Hall DJ, Eckelman WC, Vera DR, Tsien RY 2010 Oct 21 1811-1819

Parallel in vivo and in vitro selection using phage display identifies protease-dependent tumor-targeting peptides

Whitney M, Crisp JL, Olson ES, Aguilera TA, Gross LA, Ellies LG, Tsien RY 2010 Jul 285 22532-22541

Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases

Olson ES, Jiang T, Aguilera TA, Nguyen QT, Ellies LG, Scadeng M, Tsien RY 2010 Mar 107 4311-4316

Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival

Nguyen QT, Olson ES, Aguilera TA, Jiang T, Scadeng M, Ellies LG, Tsien RY 2010 Mar 107 4317-4322

Mammalian expression of infrared fluorescent proteins engineered from a bacterial phytochrome

Shu X, Royant A, Lin MZ, Aguilera TA, Lev-Ram V, Steinbach PA, Tsien RY 2009 May 324 804-807

In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer

Olson ES, Aguilera TA, Jiang T, Ellies LG, Nguyen QT, Wong EH, Gross LA, Tsien RY 2009 1 382-393

Autofluorescent Proteins with Excitation in the Optical Window for Intravital Imaging in Mammals

Lin MZ, McKeown MR, Ng HL, Aguilera TA, Shaner NC, Campbell RE, Adams SR, Gross LA, Ma W, Alber T, Tsien RY 2009 16 1169-1179

Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides

Aguilera TA, Olson ES, Timmers MM, Jiang T, Tsien RY 2009 1 371-381